BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:656-664. [PMID: 15708243 DOI: 10.1016/j.ijrobp.2004.06.022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Solidum JGN, Rojo RD, Wo JY, Dee EC. Proton Beam Therapy for Esophageal Cancer. Cancers (Basel) 2022;14:4045. [PMID: 36011037 DOI: 10.3390/cancers14164045] [Reference Citation Analysis]
2 Zhang W, Xie Q, Zhu B, Wang X, He L, Zhang Y. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study. Medicine (Baltimore) 2022;101:e29166. [PMID: 35482986 DOI: 10.1097/MD.0000000000029166] [Reference Citation Analysis]
3 Oonsiri S, Kitpanit S, Kannarunimit D, Chakkabat C, Lertbutsayanukul C, Prayongrat A. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Physics and Imaging in Radiation Oncology 2022;22:51-6. [DOI: 10.1016/j.phro.2022.04.005] [Reference Citation Analysis]
4 Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ, Sun JM. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer 2022. [PMID: 35319779 DOI: 10.1002/cncr.34176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhu H, Lu X, Jiang J, Lu J, Sun X, Zuo Y. Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma. Dose-Response 2022;20:155932582210767. [DOI: 10.1177/15593258221076720] [Reference Citation Analysis]
6 Nehlsen AD, Lehrer EJ, Resende-Salgado L, Rosenzweig KE, Buckstein M. Comparison of Pathologic Complete Response Rates and Oncologic Outcomes in Patients With Surgically Resectable Esophageal Cancer Treated With Neoadjuvant Chemoradiation to 50.4 Gy vs 41.4 Gy. Cureus 2021;13:e19233. [PMID: 34877210 DOI: 10.7759/cureus.19233] [Reference Citation Analysis]
7 Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol 2019;5:1597-604. [PMID: 31529018 DOI: 10.1001/jamaoncol.2019.2809] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 23.0] [Reference Citation Analysis]
8 Fan B, Li C, Mu F, Qin W, Wang L, Sun X, Wang C, Zou B, Wang S, Li W, Hu M. Dose escalation guided by 18F-FDG PET/CT for esophageal cancer. Radiation Medicine and Protection 2021;2:55-60. [DOI: 10.1016/j.radmp.2021.04.002] [Reference Citation Analysis]
9 Gao HM, Shen WB, Xu JR, Li YM, Li SG, Zhu SC. Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer. Int J Clin Oncol 2021;26:1640-9. [PMID: 34043101 DOI: 10.1007/s10147-021-01943-7] [Reference Citation Analysis]
10 Ikebuchi Y, Yoshida A, Kurumi H, Kamitani Y, Yasui S, Nakada Y, Kawaguchi K, Yashima K, Isomoto H. Salvage Photodynamic Therapy Using Talaporfin Sodium for Local Failure of Esophageal Squamous Cell Carcinoma. Yonago Acta Med 2021;64:120-5. [PMID: 33642911 DOI: 10.33160/yam.2021.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nayan N, Bhattacharyya M, Jagtap VK, Kalita AK, Sunku R, Roy PS. Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study. South Asian J Cancer 2018;7:27-30. [PMID: 29600230 DOI: 10.4103/sajc.sajc_178_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
13 Zhang W, Zhao J, Han W, Zhang H, Wang X, Li C, Chen J, Wang X, Zhao Y, Qiao X, Zhou Z, Han C, Zhu S, Shen W, Wang L, Ge X, Sun X, Zhang K, Hu M, Li L, Hao C, Li G, Xu Y, Wang Y, Lu N, Liu M, Qian S, Xiao Z, Wang P, Pang Q. Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). Ann Transl Med 2020;8:1140. [PMID: 33240989 DOI: 10.21037/atm-20-4672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Chen NB, Li QW, Li S, Guo SP, Wu YJ, Cheng ZJ, Li JB, Wang DQ, Liu FJ, Ai XL, Hu N, Qiu B, Liu H. Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021). Radiother Oncol. 2021;155:105-112. [PMID: 33144248 DOI: 10.1016/j.radonc.2020.10.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Qin Q, Ge X, Wang X, Wang L, Li C, Chen J, Wang X, Zhao Y, Zhang W, Wang P, Pang Q, Zhang K, Li L, Hu M, Hao C, Li G, Xu Y, Qiao X, Zhou Z, Zhu S, Shen W, Wang Y, Lu N, Liu M, Qie S, Han C, Xiao Z, Sun X. Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study. Front Oncol 2020;10:580450. [PMID: 33123483 DOI: 10.3389/fonc.2020.580450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sun X, Wang L, Wang Y, Kang J, Jiang W, Men Y, Hui Z. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis. Front Oncol 2020;10:1222. [PMID: 32850362 DOI: 10.3389/fonc.2020.01222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Kissel M, Chirat E, Annede P, Burtin P, Fumagalli I, Bronsart E, Mignot F, Schernberg A, Dumas I, Haie-Meder C, Chargari C. Esophageal brachytherapy: Institut Gustave Roussy's experience. Brachytherapy 2020;19:499-509. [PMID: 32444283 DOI: 10.1016/j.brachy.2020.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xiao L, Czito BG, Pang Q, Hui Z, Jing S, Shan B, Wang J. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. J Cancer 2020;11:4605-13. [PMID: 32489478 DOI: 10.7150/jca.44447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Zhao Z, Zhang Y, Wang X, Wang P, Geng X, Zhu L, Li M. The Prognostic Significance of Metastatic Nodal Size in Non-surgical Patients With Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:523. [PMID: 32373526 DOI: 10.3389/fonc.2020.00523] [Reference Citation Analysis]
20 Modesto A, Dalmasso C, Lusque A, Vieillevigne L, Izar F, Moyal E, Carrère N, Guimbaud R, Rives M. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. Cancer Radiother 2020;24:88-92. [PMID: 32156457 DOI: 10.1016/j.canrad.2020.01.006] [Reference Citation Analysis]
21 Li R, Shinde A, Glaser S, Chao J, Kim J, Karam SD, Goodman K, Chen YJ, Amini A. Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. J Gastrointest Oncol. 2019;10:712-722. [PMID: 31392052 DOI: 10.21037/jgo.2019.02.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel) 2019;11:E993. [PMID: 31315281 DOI: 10.3390/cancers11070993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
23 Boustani J, Rivin Del Campo E, Blanc J, Peiffert D, Benezery K, Pereira R, Rio E, Le Prisé E, Créhange G, Huguet F. Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer. Int J Radiat Oncol Biol Phys 2019;105:329-37. [PMID: 31299242 DOI: 10.1016/j.ijrobp.2019.06.2542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hammoudi N, Hennequin C, Vercellino L, Costantini A, Valverde A, Cattan P, Quéro L. Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers. Digestive and Liver Disease 2019;51:887-93. [DOI: 10.1016/j.dld.2018.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Kim TH, Lee IJ, Kim JH, Lee CG, Lee YC, Kim JW. High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study. Head Neck 2019;41:146-53. [PMID: 30548508 DOI: 10.1002/hed.25483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li HX, Liu J, Cheng Y, Liu MN, Fang WT, Lv CX. Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study. Dis Esophagus 2018;31. [PMID: 29294022 DOI: 10.1093/dote/dox144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang W, Luo Y, Wang X, Han G, Wang P, Yuan W, Dai SB. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. Cancer Manag Res 2018;10:2675-82. [PMID: 30147366 DOI: 10.2147/CMAR.S160909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Halder A, Biswas R, Ghosh A, Dastidar AG. Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study. J Contemp Brachytherapy 2018;10:225-31. [PMID: 30038642 DOI: 10.5114/jcb.2018.76843] [Reference Citation Analysis]
29 Deng W, Lin SH. Advances in radiotherapy for esophageal cancer. Ann Transl Med 2018;6:79. [PMID: 29666802 DOI: 10.21037/atm.2017.11.28] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
30 Barney CL, Zamora P, Ewing A, Old M, Chakravarti A, Bhatt A. Synchronous Supraglottic and Esophageal Squamous Cell Carcinomas Treated with a Monoisocentric Hybrid Intensity-Modulated Radiation Technique. Front Oncol 2017;7:307. [PMID: 29359120 DOI: 10.3389/fonc.2017.00307] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res 2018;10:13-21. [PMID: 29343986 DOI: 10.2147/CMAR.S144687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
32 Chen J, Guo H, Zhai T, Chang D, Chen Z, Huang R, Zhang W, Lin K, Guo L, Zhou M, Li D, Li D, Chen C. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget 2016;7:22711-9. [PMID: 26992206 DOI: 10.18632/oncotarget.8050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
33 Deng Y, Bian C, Tao H, Zhang H. Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Oncotarget 2017;8:79662-9. [PMID: 29108346 DOI: 10.18632/oncotarget.19030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
34 Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC. What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget 2017;8:89095-107. [PMID: 29179502 DOI: 10.18632/oncotarget.18760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
35 Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286-94. [PMID: 29113302 DOI: 10.18632/oncotarget.17925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 De B, Rhome R, Doucette J, Buckstein M. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis. Diseases of the Esophagus 2017;30:1-10. [DOI: 10.1093/dote/dow037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
37 Chun SG, Skinner HD, Minsky BD. Radiation Therapy for Locally Advanced Esophageal Cancer. Surg Oncol Clin N Am 2017;26:257-76. [PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
38 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
39 Kim HJ, Suh YG, Lee YC, Lee SK, Shin SK, Cho BC, Lee CG. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Res Treat 2017;49:669-77. [PMID: 27737537 DOI: 10.4143/crt.2016.354] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
40 Brower JV, Chen S, Bassetti MF, Yu M, Harari PM, Ritter MA, Baschnagel AM. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys 2016;96:985-93. [PMID: 27869098 DOI: 10.1016/j.ijrobp.2016.08.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
41 Chen Y, Zhang Z, Jiang G, Zhao K. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy. J Thorac Dis 2016;8:1155-61. [PMID: 27293832 DOI: 10.21037/jtd.2016.04.08] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
42 Chen CY, Li CC, Chien CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol 2016;120:136-9. [PMID: 27207358 DOI: 10.1016/j.radonc.2016.04.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
43 Hoeben A, Polak J, Van De Voorde L, Hoebers F, Grabsch HI, de Vos-Geelen J. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol. 2016;27:1664-1674. [PMID: 27117535 DOI: 10.1093/annonc/mdw183] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
44 Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2016;95:488-497. [PMID: 27084662 DOI: 10.1016/j.ijrobp.2015.11.043] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
45 Carrington R, Staffurth J, Warren S, Partridge M, Hurt C, Spezi E, Gwynne S, Hawkins MA, Crosby T. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiat Oncol 2015;10:236. [PMID: 26586375 DOI: 10.1186/s13014-015-0537-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 2014;9:1398-405. [PMID: 25122435 DOI: 10.1097/JTO.0000000000000267] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
47 Ge X, Yang X, Lu X, Wen W, Zhen F, Ye H, Zhu H, Cao Y, Zhang S, Cheng H, Ma J, Yang B, Dai S, Guo Q, Cai J, Sun X. Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Tumori 2015;101:168-73. [DOI: 10.5301/tj.5000234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
48 Cao C, Luo J, Gao L, Xu G, Yi J, Huang X, Wang K, Zhang S, Qu Y, Li S, Xiao J, Zhang Z. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma: clinical outcomes and patterns of failure. Eur Arch Otorhinolaryngol 2016;273:741-7. [DOI: 10.1007/s00405-015-3576-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
49 Cao C, Luo J, Gao L, Xu G, Yi J, Huang X, Wang K, Zhang S, Qu Y, Li S, Xiao J, Zhang Z. Definitive intensity-modulated radiotherapy compared with definitive conventional radiotherapy in cervical oesophageal squamous cell carcinoma. Radiol Med 2015;120:603-10. [PMID: 25644251 DOI: 10.1007/s11547-015-0510-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
50 Jiang L, Zhao X, Meng X, Yu J. Involved field irradiation for the treatment of esophageal cancer: Is it better than elective nodal irradiation? Cancer Letters 2015;357:69-74. [DOI: 10.1016/j.canlet.2014.11.045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
51 Vieillevigne L, Vidal M, Izar F, Rives M. Is dose escalation achievable for esophageal carcinoma? Rep Pract Oncol Radiother 2015;20:135-40. [PMID: 25859404 DOI: 10.1016/j.rpor.2014.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423-429. [PMID: 25304796 DOI: 10.1016/j.ijrobp.2014.06.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
53 Suh YG, Lee IJ, Koom WS, Cha J, Lee JY, Kim SK, Lee CG. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn J Clin Oncol. 2014;44:534-540. [PMID: 24771865 DOI: 10.1093/jjco/hyu047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
54 Freilich J, Hoffe SE, Almhanna K, Dinwoodie W, Yue B, Fulp W, Meredith KL, Shridhar R. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus. 2015;28:352-357. [PMID: 24635657 DOI: 10.1111/dote.12203] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
55 Strnad V, Lotter M, Kreppner S, Fietkau R. Re-irradiation with interstitial pulsed-dose-rate brachytherapy for unresectable recurrent head and neck carcinoma. Brachytherapy 2014;13:187-95. [DOI: 10.1016/j.brachy.2013.10.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
56 Lever FM, Lips IM, Crijns SP, Reerink O, van Lier AL, Moerland MA, van Vulpen M, Meijer GJ. Quantification of esophageal tumor motion on cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2014;88:419-424. [PMID: 24321785 DOI: 10.1016/j.ijrobp.2013.10.036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
57 Neumann H, Neurath MF, Vieth M, Lever FM, Meijer GJ, Lips IM, Mcmahon BP, Ruurda J, van Hillegersberg R, Siersema P, Levine MS, Scharitzer M, Pokieser P, Zerbib F, Savarino V, Zentilin P, Savarino E, Chan WW. Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease: Innovative techniques in evaluating the esophagus. Ann N Y Acad Sci 2013;1300:11-28. [DOI: 10.1111/nyas.12233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
58 Lazarescu I, Thureau S, Nkhali L, Pradier O, Dubray B. Définition du volume cible anatomoclinique pour l’irradiation des cancers de l’œsophage. Cancer/Radiothérapie 2013;17:453-60. [DOI: 10.1016/j.canrad.2013.07.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
59 Zhu H, Huo X, Chen L, Wang H, Yu H. Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer. Mol Clin Oncol 2013;1:1009-12. [PMID: 24649285 DOI: 10.3892/mco.2013.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
60 Wang YC, Chen SW, Chien CR, Hsieh TC, Yu CY, Kuo YC, Yang SN, Kao CH, Liang JA. Radiotherapy for esophageal cancer using simultaneous integrated boost techniques: dosimetric comparison of helical TomoTherapy, Volumetric-modulated Arc Therapy (RapidArc) and dynamic intensity-modulated radiotherapy. Technol Cancer Res Treat 2013;12:485-91. [PMID: 23745789 DOI: 10.7785/tcrt.2012.500348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
61 Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Salze P, Noël G. [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study]. Cancer Radiother 2013;17:221-8. [PMID: 23684111 DOI: 10.1016/j.canrad.2013.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
62 Rousseau D, Capitain O, Denis F, Girault S, Poirier A, Paumier A, Cellier P, Hamy A, Mahé M, Mesgouez-nebout N. Évolution des cancers de l’œsophage : impact de la stratégie thérapeutique. Cancer/Radiothérapie 2013;17:10-20. [DOI: 10.1016/j.canrad.2012.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz JE, Noel G. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer. Dis Esophagus 2014;27:560-7. [PMID: 23106980 DOI: 10.1111/j.1442-2050.2012.01441.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
64 Berger B, Stahlberg K, Lemminger A, Bleif M, Belka C, Bamberg M. Impact of Radiotherapy, Chemotherapy and Surgery in Multimodal Treatment of Locally Advanced Esophageal Cancer. Oncology 2011;81:387-94. [DOI: 10.1159/000335263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
65 Feeney C, Hussey J, Carey M, Reynolds JV. Assessment of physical fitness for esophageal surgery, and targeting interventions to optimize outcomes: Assessment of physical fitness. Diseases of the Esophagus 2010;23:529-39. [DOI: 10.1111/j.1442-2050.2010.01058.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
66 Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, Yin Y, Fu Z, Mu D, Zhang B, He W, Huo Z, Liu X, Kong L, Zhao S, Sun X. Comparison of 18F-Fluorothymidine and 18F-Fluorodeoxyglucose PET/CT in Delineating Gross Tumor Volume by Optimal Threshold in Patients With Squamous Cell Carcinoma of Thoracic Esophagus. International Journal of Radiation Oncology*Biology*Physics 2010;76:1235-41. [DOI: 10.1016/j.ijrobp.2009.07.1681] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
67 Wu K, Chen G, Xu Z, Fu X, Qian H, Jiang G. Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: A prospective phase I/II study. Radiotherapy and Oncology 2009;93:454-7. [DOI: 10.1016/j.radonc.2009.10.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
68 La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer: IMRT for esophagus cancer. Diseases of the Esophagus 2010;23:300-8. [DOI: 10.1111/j.1442-2050.2009.01004.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
69 Jensen AD, Grehn C, Nikoghosyan A, Thieke C, Krempien R, Huber PE, Debus J, Münter MW. Catch me if you can--the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol. 2009;185:469-473. [PMID: 19714309 DOI: 10.1007/s00066-009-1935-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
70 Hurmuzlu M, Monge OR, Smaaland R, Viste A. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome. Dis Esophagus 2010;23:244-52. [PMID: 19664075 DOI: 10.1111/j.1442-2050.2009.00999.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
71 Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. Journal of Thoracic Oncology 2009;4:880-8. [DOI: 10.1097/jto.0b013e3181a6f204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009;92:276-90. [PMID: 19375187 DOI: 10.1016/j.radonc.2009.02.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
73 Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, Bergqvist M. Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 2008;8:1433-48. [PMID: 18759695 DOI: 10.1586/14737140.8.9.1433] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
74 Moon S, Kim H, Chie E, Kim J, Park C. Positive impact of radiation dose on disease free survival and locoregional control in postoperative radiotherapy for squamous cell carcinoma of esophagus. Dis Esophagus. 2009;22:298-304. [PMID: 19021683 DOI: 10.1111/j.1442-2050.2008.00882.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
75 Créhange G, Maingon P, Bosset JF. [Radiochemotherapy for oesophageal cancer: a locoregional failure history]. Cancer Radiother 2008;12:640-8. [PMID: 18845466 DOI: 10.1016/j.canrad.2008.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
76 Chiarion-sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009;63:1111-9. [DOI: 10.1007/s00280-008-0834-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
77 Liu XH, Bai CG, Yuan Y, Gong DJ, Huang SD. Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer. World J Gastroenterol 2008; 14(10): 1575-1581 [PMID: 18330951 DOI: 10.3748/wjg.14.1575] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
78 Sasaki T, Nakamura K, Shioyama Y, Toh Y, Okamura K, Ohura H, Hirata H, Honda H. Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: a single institute experience. Am J Clin Oncol 2007;30:514-9. [PMID: 17921713 DOI: 10.1097/COC.0b013e31805c1410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
79 Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63. [PMID: 17680847 DOI: 10.1111/j.1572-0241.2007.01437.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 7.7] [Reference Citation Analysis]
80 Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2007;2:553-568. [PMID: 17545853 DOI: 10.1097/01.JTO.0000275339.62831.5e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
81 Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci 2007;98:937-42. [PMID: 17441965 DOI: 10.1111/j.1349-7006.2007.00479.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
82 Uno T, Isobe K, Kawakami H, Ueno N, Shimada H, Matsubara H, Okazumi S, Nabeya Y, Shiratori T, Kawata T, Ochiai T, Ito H. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Diseases of the Esophagus 2007;20:12-8. [DOI: 10.1111/j.1442-2050.2007.00632.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
83 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]